SG Americas Securities LLC decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 67.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,606 shares of the biopharmaceutical company's stock after selling 38,146 shares during the quarter. SG Americas Securities LLC's holdings in Xenon Pharmaceuticals were worth $857,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. DNB Asset Management AS increased its stake in shares of Xenon Pharmaceuticals by 3.8% in the fourth quarter. DNB Asset Management AS now owns 126,375 shares of the biopharmaceutical company's stock valued at $5,820,000 after purchasing an additional 4,605 shares during the period. Vanguard Group Inc. increased its stake in shares of Xenon Pharmaceuticals by 2.1% in the third quarter. Vanguard Group Inc. now owns 266,826 shares of the biopharmaceutical company's stock valued at $9,115,000 after purchasing an additional 5,473 shares during the period. Wellington Management Group LLP increased its stake in shares of Xenon Pharmaceuticals by 64.4% in the third quarter. Wellington Management Group LLP now owns 1,728,108 shares of the biopharmaceutical company's stock valued at $59,032,000 after purchasing an additional 677,057 shares during the period. Walleye Trading LLC increased its stake in shares of Xenon Pharmaceuticals by 22.1% in the third quarter. Walleye Trading LLC now owns 6,923 shares of the biopharmaceutical company's stock valued at $236,000 after purchasing an additional 1,254 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Xenon Pharmaceuticals by 40.5% in the third quarter. Walleye Capital LLC now owns 126,028 shares of the biopharmaceutical company's stock valued at $4,305,000 after purchasing an additional 36,324 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.
Insider Buying and Selling
In related news, EVP Sherrington Robin sold 7,137 shares of the firm's stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the sale, the executive vice president now directly owns 8,398 shares in the company, valued at $388,659.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Sherrington Robin sold 7,137 shares of the firm's stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the completion of the transaction, the executive vice president now owns 8,398 shares of the company's stock, valued at approximately $388,659.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven Gannon sold 13,000 shares of the firm's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $601,640.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company's stock, valued at approximately $92,560. The disclosure for this sale can be found here. 5.43% of the stock is currently owned by insiders.
Xenon Pharmaceuticals Stock Down 1.6 %
NASDAQ:XENE traded down $0.67 during trading hours on Tuesday, reaching $41.47. 237,045 shares of the company's stock were exchanged, compared to its average volume of 419,166. The company has a market capitalization of $3.13 billion, a P/E ratio of -15.25 and a beta of 1.15. Xenon Pharmaceuticals Inc. has a 12 month low of $27.99 and a 12 month high of $50.99. The business's 50-day simple moving average is $46.02 and its two-hundred day simple moving average is $40.33.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.12. Xenon Pharmaceuticals's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.57) EPS. As a group, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.04 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Royal Bank of Canada dropped their price target on shares of Xenon Pharmaceuticals from $56.00 to $55.00 and set an "outperform" rating on the stock in a research note on Friday, March 1st. Needham & Company LLC increased their price objective on shares of Xenon Pharmaceuticals from $50.00 to $62.00 and gave the company a "buy" rating in a report on Friday, March 1st. Citigroup began coverage on shares of Xenon Pharmaceuticals in a report on Thursday, January 4th. They issued a "buy" rating and a $62.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $54.00 to $59.00 and gave the company an "outperform" rating in a report on Tuesday, December 19th. Finally, Robert W. Baird began coverage on shares of Xenon Pharmaceuticals in a report on Friday, December 8th. They issued an "outperform" rating and a $63.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $58.67.
Read Our Latest Analysis on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
